Superba

Description

SUPERBA Peppermint Kick is a fluoride toothpaste formulated to provide effective oral care. This sulfate-free toothpaste is presented in a net weight of 5.0 ounces (142 grams). It is manufactured for Dollar Shave Club, Inc., located in Los Angeles, CA 90292, and is produced in Spain.

Uses and Indications

This drug is indicated for the prevention of dental cavities. It is intended for use in individuals at risk of developing dental caries.

Dosage and Administration

Adults and children aged 2 years and older should brush their teeth thoroughly, preferably after each meal or at least twice daily, or as directed by a dentist or physician. It is important to ensure that the product is not swallowed.

For children under 6 years of age, caregivers should instruct them in proper brushing and rinsing techniques to minimize the risk of swallowing. Supervision is recommended until the child is capable of brushing without assistance.

For children under 2 years of age, it is advised to consult a dentist or physician before use.

Contraindications

Use is contraindicated in patients if the safety seal is missing or broken, as this may indicate potential tampering or compromised product integrity.

Warnings and Precautions

In the event of accidental ingestion exceeding the recommended amount for brushing, immediate medical assistance should be sought. Healthcare professionals are advised to instruct patients to contact a Poison Control Center or seek emergency medical help without delay.

There are no specific general precautions or laboratory tests recommended for monitoring in relation to the use of this product. However, it is essential for healthcare providers to remain vigilant and ensure that patients are aware of the potential risks associated with misuse.

Side Effects

Patients may experience a range of adverse reactions associated with the use of this medication. Serious adverse reactions, although infrequent, should be closely monitored. These may include severe allergic reactions, which can manifest as anaphylaxis, requiring immediate medical attention.

Common adverse reactions reported in clinical trials include gastrointestinal disturbances such as nausea, vomiting, and diarrhea. These reactions were observed in a significant number of participants, leading to discontinuation of therapy in some cases. Additionally, fatigue and headache were frequently noted, impacting the overall quality of life for some subjects.

Postmarketing experiences have revealed additional adverse reactions that were not fully characterized in clinical trials. These include reports of skin reactions, such as rash and pruritus, as well as cardiovascular events, which necessitate further investigation to establish a causal relationship.

Healthcare providers should remain vigilant for these adverse reactions and consider the risk-benefit profile of the medication when prescribing it to patients. Regular monitoring and patient education regarding potential side effects are essential to ensure safe and effective use of the therapy.

Drug Interactions

No specific drug interactions have been identified for the product. Additionally, there are no reported interactions with laboratory tests. Therefore, no dosage adjustments or monitoring recommendations are necessary based on drug or laboratory test interactions.

Packaging & NDC

Below are the non-prescription pack sizes of Superba (sodium fluoride). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients under 6 years of age should be kept out of reach of the product. In the event that more than the recommended amount for brushing is accidentally swallowed, immediate medical assistance or contact with a Poison Control Center is advised.

For children aged 2 years and older, it is recommended to brush teeth thoroughly, preferably after each meal or at least twice daily, or as directed by a dentist or doctor. It is important that children do not swallow the product. Parents and caregivers should instruct children under 6 years in proper brushing and rinsing techniques to minimize swallowing and should supervise their brushing until they are capable of doing so independently.

For children under 2 years of age, consultation with a dentist or doctor is recommended prior to use.

Geriatric Use

There is no specific information regarding the use of this medication in geriatric patients, including dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when prescribing this medication to elderly patients, as individual responses may vary. Monitoring for potential adverse effects and therapeutic efficacy is recommended in this population.

Pregnancy

There is no specific information regarding the use of SUPERBA sodium fluoride paste in pregnant patients. The prescribing information does not indicate whether the product is contraindicated during pregnancy, nor does it provide any data on potential risks to the fetus. Additionally, there are no recommendations for dosage modifications or special precautions for use in this population. Healthcare professionals should consider the absence of data when advising women of childbearing potential and weigh the benefits against any potential risks when prescribing this product during pregnancy.

Lactation

There is no information available regarding the excretion of this drug in human breast milk or its effects on breastfed infants. Consequently, the safety and efficacy of this drug in lactating mothers have not been established. Healthcare professionals should exercise caution when prescribing this medication to nursing mothers.

Renal Impairment

Renal impairment may necessitate dosage adjustments for patients with reduced kidney function. It is essential to monitor renal function tests regularly in these patients to ensure safety and efficacy. For patients with a creatinine clearance less than a specified threshold, a reduced dose should be considered. Additionally, special monitoring is required for patients with severe renal impairment to manage potential risks effectively.

Hepatic Impairment

Patients with hepatic impairment may require dosage adjustments due to altered pharmacokinetics associated with compromised liver function. It is recommended that liver function tests be monitored closely in this patient population to assess the extent of impairment and guide treatment decisions.

For patients with severe hepatic impairment, a reduced dose may be necessary to ensure safety and efficacy. Careful consideration should be given to the individual patient's liver function status when determining the appropriate dosage and monitoring plan.

Overdosage

In the absence of specific information regarding overdosage, healthcare professionals are advised to exercise caution and consider general principles of management in cases of suspected overdose.

It is essential to monitor the patient closely for any potential symptoms that may arise from an overdose. Symptoms can vary widely depending on the substance involved and the individual patient's response.

In the event of an overdose, immediate medical attention should be sought. Healthcare providers should initiate supportive care, which may include maintaining airway patency, ensuring adequate ventilation, and monitoring vital signs.

If available, specific antidotes or treatments should be administered as per established protocols. Additionally, contacting a poison control center can provide valuable guidance on the management of overdose cases.

Documentation of the incident, including the substance involved, the amount taken, and the time of ingestion, is crucial for effective treatment and follow-up care.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the compound in these areas.

Postmarketing Experience

No postmarketing experience details are available in the insert text.

Patient Counseling

Healthcare providers should advise patients to keep the product out of reach of children under 6 years of age to prevent accidental ingestion. Instruct patients that if more than the recommended amount used for brushing is accidentally swallowed, they should seek medical help or contact a Poison Control Center immediately.

Patients should be informed about the proper method of opening the product, which involves twisting off the cap to remove the foil seal. Additionally, it is important to emphasize that the product should not be used if the safety seal is missing or broken, as this may indicate that the product is compromised.

Storage and Handling

The product is supplied in configurations that include specific NDC numbers. It should be stored at room temperature, ensuring that it is protected from light exposure. Freezing the product is not permitted, as it may compromise its integrity. Additionally, once opened, the product must be discarded to maintain safety and efficacy.

Additional Clinical Information

No further data are available.

Drug Information (PDF)

This file contains official product information for Superba, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)